PCa Commentary | Volume 155 – July 2021
This Commentary looks at causes and management options for hot flashes, a common side effect of ADT treatment for prostate cancer.
Read MoreSelect Page
Posted by Edward Weber, MD | Jul 2021
This Commentary looks at causes and management options for hot flashes, a common side effect of ADT treatment for prostate cancer.
Read MorePosted by Edward Weber, MD | Jun 2021
This Commentary looks at the current state of causes, diagnosis and treatment for neuroendocrine prostate cancer.
Read MorePosted by Edward Weber, MD | May 2021
This Commentary provides an overview of PSMA-targeted radioligand therapy with Lutetium-177 or Actinium-225 and positive impact on progression-free survival.
Read MorePosted by Edward Weber, MD | Apr 2021
This Commentary provides a primer on using genomic classifiers and genomic sequencing to guide management decisions for prostate cancer.
Read MorePosted by Greg Donohue | Mar 2021
This Commentary will addresses the guidance from four clinical trials regarding patient selection and imaging choices to best select patients most likely to benefit from MDT.
Read More